Emerging SARS-CoV-2 Omicron Sub-Variants JN.1 and NB.1.8.1: Genomic Evolution, Implications, and Public Health Perspectives for a variant under monitoring (VuM)
Main Article Content
Abstract
Since the onset of the COVID-19 pandemic, SARS-CoV-2 has undergone continual evolution, culminating in the emergence of multiple variants of concern (VOCs) and interest (VOIs). The Omicron (B.1.1.529) and it’s sub-lineage have dominated recent global transmission due to their enhanced infectivity and immune evasion. This review focuses on two emerging Omicron sub-variants, JN.1 and NB.1.8.1, analysing their genomic mutations, functional consequences, and public health implications. JN.1, derived from the BA.2.86 lineage (Pirola), features the unique L455S mutation in the receptor-binding domain (RBD), enhancing ACE2 binding affinity and contributing to significant immune escape. NB.1.8.1, a recombinant sub-lineage of XBB.1.9.2, accumulates multiple RBD mutations—S486P, V445P, and N460K—demonstrating convergent evolution and notable growth advantage in regions like India and the UK.
Despite their increased transmissibility and capacity for immune evasion, preliminary clinical data suggest that both sub-variants lead to predominantly mild infections, likely due to population-level hybrid immunity. However, the evolving mutation profiles raise concerns regarding reduced efficacy of monoclonal antibody therapies and the durability of vaccine protection. Comparative analyses highlight these sub-variants’ refined evolution from earlier lineages such as Alpha, Delta, and BA.1, with functional mutations enhancing both viral fitness and immune escape without compromising replication.
Thus implies importance of robust genomic surveillance, continuous vaccine efficacy evaluation, and development of broad-spectrum therapeutics. It calls for a One Health approach that integrates virological, immunological, and public health data to anticipate and respond to emerging variants. JN.1 and NB.1.8.1 exemplify the virus’s adaptive strategies under immune pressure and necessitate updated risk assessments, tailored mitigation strategies, and proactive communication to navigate the next phase of the pandemic.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Callaway E. Heavily mutated Omicron variant puts scientists on alert. Nature. 2021;600(7887):21.
3. World Health Organization. Weekly epidemiological update on COVID-19 – 30 May 2025. Geneva: WHO; 2025.
4. Gupta N, Singh B, Pandey A, Singh A, Yadav PD, Sahay RR, et al. Genomic surveillance of SARS-CoV-2 variants in India: emergence of recombinant XBB and sub-lineages. J Infect Dis. 2025;232 (5):890–900.
5. Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2022;28(3):560–9.
6. Callaway E. BA.2.86 variant—what scientists know so far. Nature. 2023;613(7943):457–8.
7. Kamble P, Daulatabad V, Patil R, John NA, John J. Omicron variant in COVID-19 current pandemic: a reason for apprehension. Horm Mol Biol Clin Investig. 2022;44(1):89–96. doi:10.1515/hmbci-2022-0010
8. Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Liu Y, et al. The SARS-CoV-2 BA.2.86 variant shows strong resistance to neutralization and enhanced receptor binding. Cell Host Microbe. 2024;32(2):153–61.e6.
9. Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, et al. Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. Science. 2022;378 (6622):1463–9.
10. Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602(7898):676–81.
11. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012.e19.
12. Yue C, Song W, Wang L, Liu D, Zhang Y, Wang X, et al. Tracking the XBB recombinant lineage and its subvariants in the global SARS-CoV-2 pandemic. Viruses. 2024;16(3):456.
13. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2023;605(7910):657–63.
14. World Health Organization. Tracking SARS-CoV-2 variants [Internet]. Geneva: WHO; 2025 [cited 2025 Jun 18]. Available from: https://www.who.int/activities/tracking-SARS-CoV-2-variants
15. Kistler KE, Bedford T. Evidence for adaptive evolution in the receptor-binding domain of seasonal coronaviruses OC43 and 229E. eLife. 2021;10:e64509.
16. Takashita E, Kinoshita N, Yamayoshi S, Fujisaki S, Iwatsuki-Horimoto K, Imai M, et al. Neutralizing activity of monoclonal antibodies against novel Omicron subvariants JN.1 and NB.1.8.1: implications for next‑generation therapeutics. JAMA Netw Open. 2025;8(6):e2523456. doi:10.10 01/jamanet workopen.2025.23456
17. Kamble P, Daulatabad V, John N, John J. Synopsis of symptoms of COVID-19 during second wave of the pandemic in India. Horm Mol Biol Clin Investig. 2021;43(1):97–104. doi:10.1515/hmbci-2021-0043
18. Kamble P, Daulatabad V, Singhal A, Zaki Ahmed, Abhishek Choubey et al. JN.1 variant in enduring COVID-19 pandemic: is it a variety of interest (VoI) or variety of concern (VoC)?. Horm Mol Biol Clin Investig. 2024;45(2):49–53. doi:10.15 15/hmbci-2023-0088
19. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19(7):409–24. doi:10.1038/s4 1579-021-00573-0
20. Plante JA, Mitchell BM, Plante KS, Debbink K, Weaver SC, Menachery VD. The variant gambit: COVID-19’s next move. Cell Host Microbe. 2021; 29(4):508–15. doi:10.1016/j.chom.2021.02.020
21. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. doi:10.1038/s4158 6-020-2012-7
22. Greaney AJ, Loes AN, Crawford KH, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3): 463–76.e6. doi:10.1016/j.chom.2021.02.003
23. Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022; 602(7898):676–81. doi:10.1038/s41586-021-04388-0
24. Wang P, Nair MS, Liu L, Iketani S, Luo Y, Guo Y, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593(7857):130–5. doi:10.1038/s41586-021-03398-2
25. Iketani S, Liu L, Nair MS, Mohri H, Wang M, Li X, et al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature. 2022;604(7906): 553–6. doi:10.1038/s41586-022-04594-4
26. Hachmann NP, Miller J, Collier AY, Ventura JD, Yu J, Rowe M, et al. Neutralization escape by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med. 2022;387(1):86–8. doi:10.1056/NEJMc2206576